Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona-Iruña, February 27, 2025 – The Navarra biotechnology companies, Palobiofarma and Medibiofarma,...
Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a statistically...
Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD...
Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi...
Pamplona-Iruña, February 2, 2024.- Palobiofarma has closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the company’s...
Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10...
[Pamplona, Spain], [May 9th, 2023] – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study...
[May 4, 2023] – [Pamplona, Navarra] – The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish...
Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-680....
